NLP 328
Alternative Names: NLP-328Latest Information Update: 18 Sep 2020
At a glance
- Originator NovaLead Pharma Pvt. Ltd
- Class Antiulcers; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Pressure ulcer; Varicose ulcer
Most Recent Events
- 08 Sep 2020 NLP 328 is available for licensing as of 08 Sep 2020. https://www.novaleadpharma.com/#about